Table 1.

General characteristics of preclinical studies investigating the efficacy of MSC therapy in models of PF

Author (year)	Country	Species, strain, gender	No. of treated animals	No. of controls	PF model	MSC source	MSC dose	MSC route	Transplant type	Time of MSC therapy after PF	Follow-up (days)
Li et al. (2017) [43]	China	Mouse C57BL/6, M	5	5	Radiation	BMSC	2.0 × 106	iv	Allograft	2 h	42 d
Xia et al. A (2015) [44]	China	Mouse, NR, NR	25	25	Radiation	BMSC	1.0 × 103	iv	Xenograft	1 d	28 d
Xia et al. B (2015)	China	Mouse, NR, NR	25	25	Radiation	BMSC	5.0 × 103	iv	Xenograft	1 d	28 d
Xia et al. C (2015)	China	Mouse, NR, NR	25	25	Radiation	BMSC	1.0 × 104	iv	Xenograft	1 d	28 d
Guo et al. (2018) [23]	China	Tree shrews, NR, F	20	20	Radiation	UCMSC	3.0 × 107	iv	Allograft	1 h, 7 d, 14 d, 21 d	28 d
F. Cahill et al. A (2016) [45]	Ireland	Mouse C57BL/6, F	5	5	BLM	BMSC	5.0 × 104	iv	Allograft	6–8 h	28 d
F. Cahill et al. B (2016)	Ireland	Mouse C57BL/6, F	5	5	BLM	BMSC	5.0 × 104	iv	Allograft	9 d	28 d
Zhang et al. (2018) [24]	China	Rat, SD, M	6	6	Silica	BMSC	2.0 × 106	iv	Allograft	28 d	28 d
He et al. (2020) [19]	China	Rat, SD, M/F	22	20	PQ	AMSC	2.0 × 106	iv	Xenograft	6 h	21 d
Moroncini et al. (2018) [46]	Italy	Mouse C57BL/6, F	8	8	BLM	UCMSC	2.5 ×  105	iv	Xenograft	1 d, 7 d	21 d
Chen et al. (2019) [10]	China	Mouse C57BL/6, M	10	10	PQ	BMSC	2.0 × 106	iv	Allograft	7 d	14 d
Tashiro et al. (2015) [47]	USA	Mouse C57BL/6, M	5	12	BLM	ADMSC	5.0 × 105	iv	Allograft	1 d	21 d
Ai et al. (2019) [48]	China	Mouse C57BL/6, M	10	10	BLM	ADMSC	5.0 × 106	iv	Allograft	1 d	14 d
Zhang et al. (2019) [20]	China	Rat, SD, M	10	10	PQ	BMSC	3.0 × 106	ip	Allograft	1 h	1 d
M. Kumamoto et al. (2009) [49]	Japan	Mouse C57BL/6, F	20	25	BLM	BMSC	5.0 × 106	iv	Allograft	3 d	10 d
Reddy et al. (2016) [50]	India	Mouse Swiss-albino, M	10	10	BLM	ADMSC	4.0 × 107	iv	Xenograft	3 d, 6 d, 9 d	21 d
Rojas et al. (2005) [51]	USA	Mouse C57BL/6, NR	5	6	BLM	BMSC	5.0 × 106	iv	Allograft	6 h	14 d
Wang et al. (2012) [40]	China	Mouse BALB/c, M	6	6	BLM	EMSC	2.0 × 105	iv	Xenograft	1 d	14 d
Lee et al. (2014) [31]	Korea	Mouse C57BL/6, M	10	20	BLM	ADMSC	3.0 × 105	ip	Xenograft	60 d	60 d
Chen et al. (2018) [52]	China	Rat, SD, M	5	5	Silica	ADMSC	5.0 × 105	iv	Allograft	1 d	28 d
Lee et al. (2010) [53]	Korea	Rat, SD, F	10	10	BLM	BMSC	1.0 × 107	iv	Allograft	4 d	28 d
Periera-simon et al. (2020) [21]	USA	Mouse C57BL/6, NR	15	15	BLM	ADMSC	5.0 × 105	iv	Xenograft	1 d	21 d
Aguilar et al. (2009) [22]	UK	Mouse C57BL/6, M	6	6	BLM	BMSC	5.0 × 106 (1 d, 3 d)	iv	Allograft	8 h	14 d
Chen et al. (2020) [54]	China	Mouse C57BL/6, M	5	5	BLM	MenSC	5.0 × 105	iv	Xenograft	2 d, 7 d	21 d
Lan et al. (2015) [38]	China	Mouse C57BL/6, F	6	6	BLM	BMSC	5.0 × 105	it	Allograft	3 d	21 d
Yuben et al. (2009) [55]	Australia	Mouse, SCID, NR	8	8	BLM	UCMSC	1.0 × 106	iv	Xenograft	1 d	28 d
Moodley et al. A (2013) [17]	Australia	Mouse C57BL/6, F	8	8	BLM	BMSC	1.0 × 106	iv	Xenograft	3 d	21 d
Moodley et al. B (2013)	Australia	Mouse C57BL/6, F	8	8	BLM	AMSC	1.0 × 106	iv	Xenograft	3 d	21 d

PF pulmonary fibrosis, SD Sprague Dawley, M male, F female, NR not reported, MSC mesenchymal stem cell, BLM bleomycin, PQ paraquat, BMSC bone marrow mesenchymal stem cells, UCMSC umbilical cord mesenchymal stem cells, ADMSC adipose-derived mesenchymal stem cells, EMSC human embryonic mesenchymal stem cells, AMSC amniotic mesenchymal stem cells, MenSC human menstrual blood–derived mesenchymal stem cells, iv intravenous, ip intraperitoneally, it intratracheally. Follow-up (days) suggests the observation time of outcomes after mesenchymal stem cell administration